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Dialyser bioincompatibility is an important factor
contributing to complications of hemodialysis with well
known systemic consequences. Here we studied the local
processes that occur on dialysis membranes by eluting
proteins adsorbed to the polysulfone dialyser membranes
of 5 patients after 3 consecutive routine maintenance
hemodialysis sessions. At the end of each procedure,
a plasma sample was also collected. These eluates and
their accompanying plasma samples were separated by
2-dimensional gel electrophoresis; all proteins that
were present in all patients were analyzed by tandem
mass spectrometry; and a ratio of the relative spot intensity
of the eluate to plasma was calculated. Of 153 proteins
detected, 84 were found in all patients, 57 of which were
successfully identified by mass spectrometry as 38
components of 23 unique proteins. In 10 spots the relative
eluate intensity differed significantly from that in the plasma,
implying preferential adsorption. These proteins included
ficolin-2, clusterin, complement C3c fragment, and
apolipoprotein A1. Our finding of a selective binding of
ficolin-2 to polysulfone membranes suggests a possible
role of the lectin complement pathway in blood-dialyser
interactions.
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Hemodialyser bioincompatibility has long been established as
an important factor in various complications accompanying
both chronic and acute hemodialysis (HD). Several aspects of
biological response triggered by blood exposure to a dialyser,
namely coagulation, complement level, and leukocyte activa-
tion, were recognized shortly after the introduction of the
artificial dialysis membrane into clinical practice.1,2 In the
past decades, we gathered comprehensive information cover-
ing metabolic consequences of these processes; that is,
chronic micro-inflammation, enhanced oxidative stress, and
pro-coagulant condition.3–6 Although difficult to link directly
with increased mortality, bioincompatibility is held (at least
partially) responsible for accelerated atherosclerosis, mal-
nutrition, and thrombotic diathesis found in HD patients.7–9
Although we have ample data regarding systemic effects of
the interaction between artificial material surface and blood,
its molecular substrates remain obscure. Yet, understanding
the mechanisms responsible for foreign pattern recognition
and launching a subsequent reaction cascade could help us to
develop better-tolerated materials, and to prevent the adverse
sequelae. Most studies addressing this issue were accom-
plished under simplified laboratory conditions (by means of
phantoms and pre-fractionated plasma),10–14 or targeted onto
a predefined set of molecules.15–22 However, to investigate the
subject in its full complexity and in an unbiased manner, the
elution of dialysers used in regular HD and in the proteomic
approach is crucial.
Therefore, the aim of our study was to verify the elution
algorithm eligible for proteomic analysis, to highlight the
eluate proteome, and to qualify the potential molecules
involved in the blood–dialyser interaction. To the best of our
knowledge, this is the first trial studying with proteomic
method the full spectrum of proteins adsorbed by a
hemodialyser in a clinical setting.
RESULTS
The protein concentrations of both eluate (acetic acid) (449
(98.9, 2487.3)mg/l) and washout (ethylenediaminetetra-
acetic acid in phosphate buffered saline, PBS/EDTA) (260.3
(156, 779.4)mg/l) were significantly higher (Po0.001) than
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in the final 10-ml flush (Plasmalyte) (24.4 (19.2, 27.6)mg/l).
The difference in protein concentrations between eluate and
washout was not statistically significant (P¼ 0.17). Although
the variation in protein content was relatively low in the flush
(coefficient of variation, CV¼ 22%), it was considerably
higher in the washout (CV¼ 152%) and in the eluate
(CV¼ 154%). Nevertheless, protein concentrations were
closely correlated in the latter two samples (r¼ 0.82,
Po0.001).
In total, 45 gels derived from 15 dialyser eluates and the
corresponding plasma samples were analyzed. A representa-
tive two-dimensional (2D) gel-scanned image is shown in
Figure 1 to demonstrate the typical eluate proteome map.
There were 153 spots detected in at least one eluate sample,
84 of them were found in all 5 patients, and 44 were present
in all procedures. Protein spots were distributed along the
molecular weight (MW) range of 15–175 kDa and pI range of
3.4–8.9. However, 95% of the overall protein spot intensity
was localized inside the interval of MW of 18–85 kDa and pI
of 3.4–7.7. Besides that, samples of the PBS/EDTA washout
from three dialysers were used to prepare another nine gels
and compared with corresponding plasma and eluate spot
patterns. As all the spots detected in the washout were
present in the acetic eluate as well, and the quantitative
analysis of relative spot intensities did not show any
significant differences between the washout and plasma, only
acetic eluates were submitted for further analysis.
Spot distribution is shown in Figure 2. Spots detected in
all patients (n¼ 84) were excised from gels; 57 spots (those
labeled with numbers in Figure 1) were successfully identified
by mass spectrometry (MS) and tandem mass spectrometry
(MS/MS) analyses as 38 components of 23 unique proteins
(Table 1). Some of the identified spots contained multiple
isoforms of one protein (most likely because of post-
translational modifications), for example, ficolin-2 (spot
nos. 31–35) or clusterin (spot nos. 23–25). The protein identifica-
tions were further verified by the comparison of measured pI
and MW (estimated by the coordinates of the spots in gel)
with their theoretical values (as predicted by the protein
database). Confirmed identifications are marked with an
asterisk in Table 1. Discrepant MWs were common particu-
larly in albumin (spot nos. 28, 29, 38–40) and in hemoglobin
(spot nos. 30, 42, 44) co-migrated with another protein.
In several protein spots (that is, complement C3,
mannose-binding lectin-associated serine proteases (MASP)
1 and 2), the measured MWs were lower than the theoretical
ones. This difference could be explained by the enzymatic
cleavage of their inactive forms. Figure 3 illustrates peptide
fragments and amino acid sequences of these proteins
established with MS and MS/MS analyses, and indicates the
presence of proteolytic cleavage products rather than full-
length or native forms. Moreover, MW and pI measured
in 2D gels corresponded better with the theoretical values
of their respective fragments: C3 complement (spot no. 26;
measured MW: 37 kDa, pI: 4.8) vs C3c a-chain fragment 2
(theoretical MW: 39.5 kDa, pI: 4.8); MASP-1 (spot no. 47;
measured MW: 44 kDa, pI: 4.0) vs MASP-1 heavy chain
(theoretical MW: 49 kDa, pI: 4.9); and MASP-2 (spot no. 48;
measured MW: 39 kDa, pI: 5.5) vs MASP-2A (theoretical
MW: 47.7 kDa, pI: 5.4).
The variability of eluate intensities of the corresponding
spots among patients (CV inter-individual) ranged from 6 to
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Figure 1 |Representative two-dimensional gel image of
dialyser eluate. Spots labeled with numbers were successfully
identified by tandem mass spectrometry analyses (see Table 1).
MW, molecular weight.
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Figure 2 |Basic characteristics of proteins detected in dialyser eluate. (a) Molecular weight (MW) and (b) pI distributions of proteins
in dialyser eluate. Percentage per category of total spot number are given.
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Table 1 | Proteins identified in eluates from dialysers used in clinical hemodialysis
Spot
no. Protein name
Swissprot
entry
PMF score/sequence
coverage
MSMS peptide no./total ion
score
CV inter-individual
(%)
E/P
ratio
1 78 kDa glucose-regulated proteina P11021 107/29% 4/110 36 0.65
2 Actin, a-cardiac muscle 1a P68032 60/25% NA 81 1.74
Actin, cytoplasmic 1a P60709 174/51% 9/723
3 Actin, cytoplasmic 1a P60709 64/45% 4/203 53 NM
4 Actin, cytoplasmic 1a P60709 NA 1/56 26 1.19
5 Albumina P02768 260/69% 10/833 6 0.83
6 a-1-Antitrypsina P01009 162/52% 4/413 13 0.93
7 a-1-Antitrypsina P01009 194/54% 6/542
8 a-1-Antitrypsina P01009 226/52% 6/425
9 a-1-Antitrypsina P01009 140/43% 4/238
10 a-1B-glycoprotein P04217 113/33% 5/273 25 0.82
11 a-1B-glycoprotein P04217 180/41% 8/261 17 0.92
12 Antithrombin-III P01008 NA 1/52 25 NM
13 Apolipoprotein A-Ia P02647 77/22% 6/234 45 0.73
14 Apolipoprotein A-Ia P02647 121/50% 5/327 18 2.06#
15 Apolipoprotein A-Ia P02647 NA 1/37 38 29.89#
Peroxiredoxin-2a P32119 132/41% 7/426
16 Apolipoprotein Ea P02649 240/71% 9/962 176 11.44
17 Apolipoprotein Ea P02649 113/41% 5/133
18 b-2-Glycoprotein 1 P02749 95/48% 5/292 66 0.70
Ig a-1 chain C P01876 NA 4/72
19 b-2-Glycoprotein 1 P02749 83/47% 6/401 52 0.27#
Ig a-2 chain C P01877 NA 4/221
20 b-2-Glycoprotein 1 P02749 59/20% 3/132 22 0.24#
Ig a-2 chain C P01877 NA 1/31
21 b-2-Glycoprotein 1 P02749 NA 1/44 49 0.52
22 Carbonic anhydrase 1a P00915 NA 4/279 69 NM
Flavin reductase P30043 NA 1/48
23 Clusterina P10909 71/34% 2/112 90 9.08#
24 Clusterina P10909 NA 3/61
25 Clusterina P10909 NA 1/76
Apolipoprotein Ea P02649 132/29% 6/135
26 Complement C3 P01024 66/13% 8/452 55 3.20#
27 Complement factor Ha P08603 103/18% 6/394 79 NM
28 Complement factor H-related
protein 1
Q03591 NA 2/109 152 NM
Albumin P02768 95/25% 5/186
29 Fibrinogen g-chaina P02679 94/47% 3/37 88 0.52
Albumin P02768 118/22 2/84
30 Fibrinogen b-chaina P02675 NA 3/81 31 0.275
Hemoglobin subunit-a P69905 NA 2/152
Hemoglobin subunit-b P06727 NA 4/181
31 Ficolin-2a Q15485 NA 2/49 60 26.12##
32 Ficolin-2a Q15485 132/52% 6/554
33 Ficolin-2a Q15485 93/44% 7/470
34 Ficolin-2a Q15485 119/44% NA
35 Ficolin-2a Q15485 85/28% 5/419
36 Haptoglobin P00738 91/28 6/353 29 0.88
Apolipoprotein A-IVa P06727 45/17% NA
37 Haptoglobina P00738 NA 1/31 14 0.94
Apolipoprotein A-IVa P06727 206/44% 8/441
38 Haptoglobina P00738 88/17% 3/112 41 1.41
Albumin P02768 159/34% 6/336
39 Haptoglobina P00738 NA 4/217 41 1.37
Albumin P02768 177/41% 7/451
40 Haptoglobina P00738 NA 5/60 46 0.91
Albumin P02768 122/37% 5/261
41 Haptoglobin P00738 NA 4/224 57 1.82
42 Hemoglobin subunit-a P69905 59/58% 5/382 32 4.82#
Hemoglobin subunit-b P06727 101/78% 2/82
Ig k-chain C P01834 NA 4/407
43 Hemoglobin subunit-aa P69905 NA 2/152 39 39.22#
Hemoglobin subunit-ba P06727 NA 4/181
44 Ig g-1-chain C P01857 74/41% 2/86 72 6.04
Ig g-2-chain C P01859 89/34% 4/130
Table 1 continues on following page
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176% (Table 1), whereas the method variability (mean CV
inter-gel) reached 27%. A comparative analysis of the eluate
proteome to matched plasma profile of the respective
patients revealed significant differences (with 4two-fold
changes in the eluate-to-plasma (E/P) ratio, Po0.01) in
levels of 10 proteins (Table 1). Relative intensities of high-
abundant plasma proteins (albumin, transferrin, hapto-
globin, a-1-antitrypsin) in eluates were similar to plasma
(E/P¼ 0.5–2) (Table 1). Only fibrinogen b- and g-chains were
depleted in eluates (spot no. 30, E/P¼ 0.28 and spot no. 29,
E/P¼ 0.52, respectively), whereas immunoglobulin light
chains seemed enriched (spot no. 42, E/P¼ 4.8) (Table 1).
Nevertheless, the latter spot was co-migrated with hemoglo-
bin a- and b-chains, and the spot intensity varied profoundly
among samples. In several low-abundant plasma proteins,
pronounced differences in eluate and plasma intensities were
detected ranging from E/P¼ 3.2 (P¼ 0.007) for complement
C3 (spot no. 26; Figure 4) to E/P¼ 26.1 (Po0.001) in the case
of ficolin-2 (spot nos. 31–35 cumulative intensity; Figure 4).
Figure 5 shows quantitative data of plasma proteins, the levels
of which were significantly higher in eluates than those in the
plasma. Naturally, several intracellular proteins, for example,
hemoglobin (spot no. 43) or peroxiredoxin (spot no. 15), reached
an even higher E/P ratio (39 and 29, respectively), or were
not matched to plasma at all (spot no. 22; carbonic anhydrase,
flavin reductase). Therefore, hemoglobin was considered the
major contaminant released from erythrocytes entrapped
within the dialysers. To avoid an error in the assessment of
eluate protein quantities (and consequently E/P ratios), spots
containing hemoglobin were excluded from the integrated
spot density while calculating relative intensities.
DISCUSSION
Proteins adsorbed to the polysulfone dialysis membrane
during clinical HD were investigated using proteomic tools in
five patients treated with chronic HD. A stepwise elution of
the dialysers was performed following routine procedures,
thrice in each patient. Proteins thus obtained were separated
by electrophoresis on two-dimensional polyacrylamide gels
(2-DE), and their relative intensities were measured. The
results were then compared with the corresponding plasma
protein patterns. Prominent spots were excised and identified
by MS.
To minimize the contamination of desorbed proteins, we
adopted a sequential elution algorithm. As soon as the
patient was disconnected, the dialyser was flushed with saline
to remove the residual plasma and cells. Protein concentra-
tion in the final 10ml of this flush was negligible (compared
with plasma) and similar in all patients, suggesting simple
kinetics of plasma washout. In the next step, we applied
EDTA solution, which had been shown earlier to detach
adhering leukocytes more effectively than PBS alone.23
Finally, elution with acetic acid was performed, because it had
been used successfully to solubilize adsorbed proteins while
preserving them for proteomic analysis.24 Protein denatura-
tion and solubilization, necessary for 2D electrophoresis, can
Table 1 | Continued
Spot
no. Protein name
Swissprot
entry
PMF score/sequence
coverage
MSMS peptide no./total ion
score
CV inter-individual
(%)
E/P
ratio
Hemoglobin subunit-a P69905 NA 2/152
Hemoglobin subunit-b P06727 NA 4/181
Complement factor H-related
protein 1a
Q03591 91/31% 5/300
45 Ig k-chain C region P01834 56/75% 3/269 21 0.44#
Ig l-chain C regions P01842 NA 1/100
46 Lysozyme C P61626 NA 1/47 116 NM
Proline-rich protein 4 Q16378 NA 1/30
47 Mannan-binding lectin serine
protease 1
P48740 81/21% 6/374 77 NM
48 Mannan-binding lectin serine
protease 2
O00187 NA 2/70 17 NM
49 Plastin-2a P13796 70/27% 3/245 29 0.75
50 Serotransferrina P02787 NA 2/62 19 1.04
51 Serotransferrina P02787 65/13% 2/92
52 Serotransferrina P02787 82/20% NA
53 Serotransferrina P02787 170/27% 8/561
54 Serum amyloid Pa P02743 60/24% 4/134 19 1.10
55 Vimentina P08670 289/65% 10/726 16 1.04
56 Vitamin D-binding proteina P02774 NA 4/339 28 1.13
Vimentina P08670 193/46% 6/271
57 Vitamin D-binding proteina P02774 105/31% 8/536 91 1.46
CV, coefficient of variance; E/P, eluate-to-plasma ratio of relative spot intensities; MSMS, tandem mass spectrometry; MW, molecular weight; NA, not applicable (identification
by mass spectrometry (MS) or tandem mass spectrometry (MS/MS) was not done or was unsuccessful); NM, not matched (eluate spot could not be matched with plasma
unambiguously); PMF, peptide mass fingerprinting.
Mean E/P ratios (from five patients, three hemodialysis procedures each) are given for all proteins matched to plasma. Relative protein spot intensities were compared in
eluates and plasma (#Po0.01, ##Po0.001).
For proteins represented by multiple spots, cumulative intensities of all spots were used to calculate CV and E/P. Therefore, only one value is given for each variable covering
all spots containing a specific protein.
aSpots whose measured MW and pI were in agreement with their theoretical values.
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be achieved by means of acidic, alkaline, chaotropic, or
detergent agents. Ishikawa et al.24 report, having tested
acetic acid, bicarbonate, urea, and sodium dodecylsulfate
(SDS) to find, acetic elution to be the most efficient. This
observation has been confirmed by us; acetic acid has been
shown to be superior to SDS in a preliminary sequential
elution study (see Supplementary Table 1).
In our experiment, recirculation with PBS/EDTA yielded a
protein at a concentration an order of magnitude higher than
the final portion of PBS flush. This protein gain can be
explained by the release of proteins attached to the dialyser,
considering the inert nature of PBS, probably because of
convective forces and equilibrium shift between adsorp-
tion and desorption occurring in a protein-free medium.
Moreover, the protein profile of the PBS/EDTA washout
resembled that of acetic eluate (see Supplementary Figure 1).
The following elution with acetic acid induced an additional
discharge of more firmly bound proteins, which even slightly
exceeded the first one. Taking into account the high variation
of the protein content, the adsorption seems to be patient-
and procedure-dependent. The described advantage of acidic
eluent over other solvents can be theoretically attributed to
the surface negativity of polysulfone membrane (z-potential
5mV), which would be suppressed by strong anions thus
dissociating electrostatic bindings.
In eluates, the complete spectrum of MW and pI fractions
detectable with the 2-DE technique was discovered, thus
substantiating the use of proteomic rather than the targeted
approach. Of the 153 protein spots, 84 were present in all
patients constituting the typical proteome adsorbed to a
hemodialyser during clinical HD. Among them, 23 unique
proteins were identified with MS. Most of them were
plasma proteins, both high (serum albumin, transferrin,
a-1-antitrypsin, haptoglobin, immunoglobulin chains) and
low abundant (MASP-1 and MASP-2, ficolin-2, clusterin,
etc.). However, several proteins arose from the blood cells,
mainly erythrocytes (hemoglobin a- and b-subunits, peroxi-
redoxin, carbonic anhydrase).
The only available trial addressing a similar issue with pro-
teomic technology was performed ex vivo, using minidialysers
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Figure 3 |Peptide fragments and sequence coverage of complement C3 and mannose-binding protein-associated serine protease-1
(MASP-1) identified in dialyser eluate. Complement C3 (a) and MASP-1 (b) amino acid sequences (in one-letter code). C3c a-chain
fragment 2 (1321–1663) and MASP-1 heavy chain (20–448) are framed within a box. Peptides covered by peptide mass fingerprinting are
highlighted in bold; sequences confirmed by tandem mass spectrometry are underscored.
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composed of cellulose diacetate or ethylenevinyl alcohol,
and blood treated with EDTA.13 Nine proteins, mostly high
abundant, were identified in this model, all of which were
also detected in our setting, except aspartyl-tRNA synthetase.
Yet, none of these proteins were clearly related to comple-
ment, coagulation, or leukocyte activation.
Mulzer and Brash 20 selected 16 plasma proteins, mainly
those engaged in blood clotting and complement activa-
tion, and tested their presence in various dialyser eluates
using specific immunoassays. All high-abundance proteins
reported in this experiment were also identified by us,
namely albumin, transferrin, immunoglobulin, fibrinogen,
a-1-antitrypsin, apolipoproteins, and haptoglobin. Mulzer
and Brash20 found the adsorption of low-abundance proteins
to be largely dependent on the dialyser type. Cuprophane,
which is considered standard in terms of bioincompatibility,
bound substantially various cleavage products of HMWK
(high MW kininogen), antithrombin III, C3 (mainly C3c
and C3d), fibronectin, and a2-macroglobulin. Of these, the
C3c fragment and antithrombin III stained as strong bands
during immunoblot and were also confirmed in our study.
The absence of HMWK, fibronectin, and a2-macroglobulin
fragments in our experiment may reflect different properties
(biocompatibility) of polysulfone, as well as the lower sen-
sitivity of MS detection (respective bands were assessed as
moderate or weak by Mulzer and Brash 20).
Several lines of references indicate that many of the
adsorbed proteins identified in this study are involved in
blood–dialyser interaction. These included complement C3,
ficolin-2, clusterin, MASP-1, MASP-2, complement factor H,
and complement factor H-related protein 1, which partici-
pate in complement activation, as well as25–30 fibrinogen,
antithrombin, and b-2-glycoprotein-1, which control blood
coagulation,31,32 and serum amyloid P, which mediates
leukocyte adhesion and activation.33 To ascertain proteins
undergoing selective adsorption, and hence possibly a spe-
cific interaction with the dialyser membrane, we calculated
E/P ratios. Although 2-DE allows only estimation of protein
quantities, and low E/P may be caused by imperfect elution,
as well as by lack of affinity to the dialyser; it is reasonable to
consider high E/P as evidence of preferential binding. In this
manner, the relevance of ficolin-2 and clusterin has been
emphasized.
Ficolin-2 (MW¼ 34 kDa, its synonyms include L-ficolin
and hucolin) is a lectin family member secreted in the
plasma, and complexed with serine proteases, particularly
MASP-1 and MASP-2. It acts as a soluble pattern recognition
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Figure 4 | Enlarged images of corresponding sections in
gels derived from dialyser eluate and plasma. Significant
differences in relative intensities of plasma proteins identified
in (a) dialyser eluate compared with (b) plasma. The highest
eluate-to-plasma ratio (E/P) of spot intensity was detected in
ficolin-2 (spot nos. 31–35), clusterin (spot nos. 23–25), and
complement C3c fragment (spot no. 26).
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Figure 5 |Plasma proteins identified in dialyser eluate and that reached significantly different relative spot intensities in eluate vs
plasma. Statistical significance was tested using Mann–Whitney rank sum test.
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protein, which upon binding to polysaccharide bacterial wall
promotes auto-cleavage of MASPs, and thus initiates the
lectin complement pathway.34 In addition, it has an opsonic
activity,35,36 and both MASP proteases cleave prothrombin
and trigger blood clotting.37,38 The role of the lectin pathway
in biomaterial-induced inflammation has not been evaluated
so far, and both alternative and classical pathways have been
attributed major significance. According to the accepted
models, the classical pathway accounts for the initiation of
the process, whereas the alternative pathway (demonstrated
by complement factor B conversion) is responsible for its
amplification.39 Nevertheless, it may be difficult to discern
the classical from the lectin pathway, as most studies dealing
with this issue determine complement activation according
to C5a or C4a levels, and this part of the cascade is shared by
both pathways. Namely, the activated MASP cleaves C4, which
in turn activates C2 thus, giving rise to C3 convertase (C4b2a);
C3b is central to all the three pathways. Substrate specificity of
the ficolins has been addressed before, and includes various
kinds of acetylated oligosaccharides;40,41 however, a possible
capacity of polysulfone membrane to activate ficolin-2 and
associated MASP should be confirmed directly.
Our data show excessive binding of ficolin-2 (spot
nos. 31–35; E/P¼ 26.1) in a clinical setting together with C3c
fragment (spot no. 26; E/P¼ 3.2). C3c is a degradation product
of activated C3b providing evidence of both C3 activation
and subsequent C3b inactivation. Relative abundance of
C3c in eluates from cuprophane dialysers was reported in
early studies, whereas only minimal amounts of C3d were
obtained.20,42 This is easily comprehensible as the latter
fragment contains the thioester site covalently binding to the
surface,43 and its release is not probable under the described
elution conditions. Moreover, we documented the concurrent
presence of the activated forms of MASP-1 (spot no. 47) and
MASP-2 (spot no. 48)44, which infer a possible connection
between ficolin adsorption and C3 activation. Therefore, it is
conceivable that ficolin-2 adsorption and lectin pathway
contribute to complement activation, as well as leukocyte
adhesion and perhaps even blood coagulation.
Factor H adsorption to polyanionic surfaces recognized as
‘self ’ and the subsequently enhanced degradation of C3b have
been shown to play a role in tissue protection from improper
complement-dependent lysis.29,30,45 Yet, complement factor
H and its related protein-1 (key regulatory molecules of the
alternative pathway) detected in our experiment showed low
relative quantities, and were hardly matched with the plasma
(complement factor H has MW 4130 kDa, and was located
in a low-resolution area on 13% gels). Quite speculatively,
adsorption of factor H and its related protein 1, evidenced in
our study, could be, in part, responsible for the accelerated
turnover of C3b (we showed the adsorption of its cleavage
fragment C3c only; no intact C3b was observed).
Another candidate biocompatibility factor derived from
our results is clusterin (complement cytolysis inhibitor, spot
nos. 23–25; E/P¼ 9.1), which is a plasma protein consisting
of two non-identical subunits (eachB35 kDa). Clusterin has
been shown to interfere with the soluble membrane attack
complex (C5b-9) formation, and to prevent (or limit)
cytolysis in this manner.46 Biological consequences of its
adsorption are difficult to predict; we may hypothesize that
enhanced clearance of clusterin by binding to the dialyser
membrane could increase the burden brought about by
complement activation due to lack of circulating clusterin
(as observed in experiment).47
In several other proteins, their role in the blood–
dialyser interaction (while plausible) is difficult to define.
The b-2-glycoprotein-1 is an important inhibitor of the
contact phase system neutralizing negatively charged surfaces
and suppressing the intrinsic blood coagulation pathway.
Binding of the b-2-glycoprotein-1 to a dialyser might have a
favorable effect on thrombogenicity, yet its eluate quantity
was significantly decreased (E/P below 0.5). Nevertheless, its
spots on the 2D gels overlapped with the immunoglobulin
heavy chains fraction, which might have substantially
corrupted the quantification. It has been proposed that actin
and vimentin co-assemble under the guidance of fimbrin
(L-plastin) at the cell adhesion sites of macrophages.48 All
these proteins were identified in the dialyser eluate; how-
ever, it is questionable whether their presence in the eluate
predicates more than leukocyte lysis.
In summary, we report an elution technique allowing the
preparation of proteins adsorbed to a dialyser during clinical
HD. The proteins obtained were subjected to gel electro-
phoresis and subsequently to MS to show their applicability
for proteomic profiling. To screen out proteins undergoing
preferential adsorption, and hence presumably a specific
interaction with the dialyser, we calculated the E/P ratios of
relative spot intensities. The proteins concentrated signifi-
cantly in the eluate were considered to be potentially engaged
in the blood–dialyser interaction. These criteria were met,
especially in ficolin-2 and clusterin, both of which play an
important role in complement activation (ficolin-2 is also
a potent opsonic agent). With respect to our data, we
hypothesize that the lectin pathway could contribute to
complement activation occurring on contact of human blood
with the polysulfone hemodialyser.
MATERIALS AND METHODS
Patients and treatment
Patients were recruited at the Hemodialysis Center of the Charles
University Teaching Hospital in Plzen, and the study protocol was
approved by the Institutional Ethics Committee. Inclusion criteria
were as follows: regular HD for more than 3 months, established
4-h dialysis thrice a week with F6 dialyser (polysulfone, 1.3m2,
Fresenius Medical Care, Bad Homburg, Germany), native arterio-
venous shunt allowing blood flow for 300ml/min or more, and
heparin anticoagulation with a total dose (bolusþ continuous)
4000–6000 i.u. as per procedure. Patients meeting the following
criteria were excluded from the study: current or past anti-
coagulation treatment (oral or parenteral) other than during the
dialysis session, history of thrombotic complication or known
coagulation disorder, diabetes mellitus, active inflammation,
malignancy, or liver disease. Within a 3-week screening period,
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the heparin dose was maintained, and the proportion of the
dialyser filled with coagulum was assessed visually at the end of
every procedure. A semi-quantitative scale commonly used in the
center was applied (1¼ no visible clot; 2¼ up to 50% capillaries in
the dialyser filled with clot; 3¼more than 50% capillaries filled with
clot; 4¼macroscopic coagulum in the lines, outside the dialyser;
5¼ complete obstruction of the extracorporeal circuit), and only
patients with a score of 1 or 2 were considered eligible.
Finally, five patients aged 58–82 years, treated with HD for 5–42
months were included in the study. In this group, hemodialysers
were eluted on three consecutive procedures, following the protocol
described below. All HD sessions were performed routinely; that is,
blood flow (300ml/min), dialysate flow (500ml/min), and ultra-
filtration rate (250–500ml/h). At the end of the HD session, 4ml of
plasma was collected, and blood residuum left in the lines was
retrieved using 250-ml rinse (Plasmalyte, Baxter, Deerfield, IL,
USA). Thereafter, the patient was disconnected from the system
and the dialyser was flushed immediately with another 1000ml
Plasmalyte solution. The final 10ml of this flush was gathered from
the dialyser outlet and stored at 801C.
Elution protocol and sample preparation
The F6 dialyser has a declared priming volume of 78ml. Initially, it was
emptied and directly filled with 80ml of 3mM EDTA (EDTA/PBS,
pH¼ 7.4), thereafter it was re-circulated with the peristaltic pump (flow
rate: 80ml/min) at 241C for 30min to detach and wash out adhering
leukocytes. The dialyser was drained thereafter; the obtained fluid was
centrifuged at 1200 g at 41C for 10min. The supernatant, denoted as
washout, was separated from the sediment containing cells and stored
at 801C. The dialyser was immediately loaded with 80ml of 40%
acetic acid, re-circulated again with a flow rate of 80ml/min at 241C
for 30min, emptied, and the resulting eluate was centrifuged at 4000 g
at 41C for 10min to remove cellular detritus, and stored at 801C.
To minimize salt contamination, eluates were dialyzed against
ultra-high quality water at 41C (10 exchanges, 1.5 l each) using a semi-
permeable membrane with a molecular mass cutoff at 7 kDa (Serva-
Electrophoresis, Heidelburg, Germany) for 5 days. Dialyzed samples
were concentrated by vacuum evaporation (SpeedVac, Thermo Fisher
Scientific, Waltham, MA, USA), and the proteins were dissolved in a
lysis buffer (7M urea, 4% 3-[(3-Cholamidopropyl)dimethylammonio]-
1-propanesulfonate, 40mM Tris base, 2M Thiourea, 2% immobilized pH
gradient, IPG, buffer pH 3–10, 120mMdithiotreitol, DTT). Blood samples
(4ml) were processed by centrifugation only (at 4000 g and 41C for
10min) to separate plasma (supernatant). Protein concentrations in all
samples were assessed using Bradford’s dye-binding assay (Bio-Rad
Protein Assay, Bio-Rad Laboratories, Hercules, CA, USA).
To assess the effectivity of the elution process, we performed
additional studies evaluating a sequential elution with an SDS
detergent. Two dialysers were eluted consecutively either with
40% acetic acid followed by 10% SDS or vice versa. The protein
quantities obtained were 9.33 and 0.014mg using the eluent
sequence acetic acid–SDS, whereas 6.99 and 2.85mg were eluted
when the inverse order was used. However, in case of SDS sub-
sequent to acetic elution, the protein concentration (0.21mg/ml) was
at the detection limit of the method.
Two-dimensional electrophoresis
Urea, CHAPS, Tris base, thiourea, SDS, DTT, IAA (iodacetamide),
and bromphenol blue used during the preparation were purchased
from Sigma (Sigma-Aldrich, Steinheim, Germany); immobilized
IPG buffer (ZOOM carrier Ampholytes 3–10) was purchased from
Invitrogen (Invitrogen Corporation, Carlsbad, CA, USA). Equally,
200-mg proteins in both the eluate and plasma samples were mixed
with rehydration buffer (7M urea, 4% CHAPS, 40mM Tris base,
2M Thiourea, 2% IPG buffer pH 3–10, 120mM DTT, and a trace of
bromophenol blue) to obtain the final volume of 140 ml. Samples
were then rehydrated in IPG strips (7.7-cm length, pH 3–10
nonlinear; Invitrogen), and focused in a MiniProtean cell (Bio-Rad).
IPG strips were rehydrated passively for 1 h and actively for 10 h at
30V, followed by a stepwise isoelectric focusing (IEF) as follows:
200V until 400Vh were reached, 450V for another 500Vh, 750V
for another 900Vh, and finally 2000V for the other 10,000 Vh. After
isoelectric focusing, the IPG strips were equilibrated in the equili-
bration buffer 1 (112mM Tris-base, 6M urea, 30% v/v glycerol,
4% w/v SDS, 130mM DTT, and a trace of bromophenol blue) for
30min, and subsequently alkylated in buffer 2 (112mM Tris-base,
6M urea, 30% v/v glycerol, 4% w/v SDS, 135mM IAA, and a trace of
bromphenol blue) for 30min. Each equilibrated IPG strip was placed
on the top of a 13% polyacrylamide gel (9 7 cm) and covered with
0.5% agarose. Second-dimension separation was performed with
65mA per gel at 201C until the bromophenol blue dye front reached
the bottom of the gel. At the end of each run, the 2D gels were
stained with Simply Blue (Invitrogen), and scanned with an Epson
Perfection 4990 Photo scanner (Epson, Long Beach, CA, USA).
2-DE pattern analysis and statistics
Computer-aided analysis of 2-DE gel images was carried out using
PDQuest 2D software version 8.1 (Bio-Rad). A synthetic image was
constructed out of the triplicated gels processed from each sample,
using only the spots constantly present in at least two gels. The
protein quantity was determined relative to the integrated spot
density. The intensity levels of the protein spots in the eluate
samples were compared with those of the corresponding or matched
spots of the plasma samples collected from the same patients, and
expressed as E/P ratios. Quantitative differences were considered
significant when showing at least a two-fold intensity variation. The
statistical analysis was performed using the SigmaPlot/SigmaStat
data analysis software (version 12.0, SPSS Inc., Chicago, IL, USA).
The inter-gel variability was determined as the CV of relative spot
intensities across triplicates. Moreover, the inter-individual vari-
ability (CV among patients) was assessed in identified spots.
Mann–Whitney rank sum test was used to compare the continuous
variables. Data are given as medians (ranges), differences were
considered statistically significant if the P-values were below 0.01.
In-gel tryptic digestion
Acetonitrile (ACN), ammonium bicarbonate, DTT, IAA, TFA
(trifluoroacetic acid), formic acid, and CHCA (a-cyano-4-hydroxy-
cinnamic acid) were purchased from Sigma. Spots detected in all
patients were excised manually. The SimplyBlue stain (Invitrogen
Corporation, Carlsbad, CA, USA) was removed by washing with
50mM ammonium bicarbonate and ACN. Proteins in the gel were
reduced with 10mM DTT/50mM ammonium bicarbonate at 561C for
45min and alkylated with 55mM IAA/50mM ammonium bicarbonate
(for 30min, in the dark at room temperature). Gel plugs were washed
with 50mM ammonium bicarbonate and ACN and dried by SpeedVac.
Dried gel particles were rehydrated with a digestion buffer containing
12.5 ng/ml sequencing grade trypsin (Roche, Basel, Switzerland) in
50mM ammonium bicarbonate at 41C. After 45min, the remaining
solution was removed and replaced by 0.1M ammonium bicarbonate.
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Tryptic digestion was performed overnight (371C). After digestion,
proteolytic peptides were subsequently extracted with 25mM ammo-
nium bicarbonate, ACN, and 5% formic acid. The three extracts were
pooled and 10mM DTT solution in 50mM ammonium bicarbonate
was added. The mixture was then dried using SpeedVac and the
resulting tryptic peptides were dissolved in 5% formic acid solution
and desalted using ZipTip mC18 (Millipore, Bedford, MA, USA).
MALDI (matrix-assisted laser desorption/ionization)
TOF (time-of-flight) tandem MS and protein identification
Proteolytic peptides were mixed with CHCA matrix solution (5mg/ml
CHCA in 0.1% TFA/50% ACN 1:1, v/v) in a 1:1 ratio, and 0.8ml of this
mixture was spotted onto the MALDI target. All mass spectra were
acquired at a reflectron mode using a 4800 MALDI TOF/TOF Analyzer
(Applied Biosystems, Framingham, MA, USA). A total of 2000 and
3000 laser shots were acquired and averaged to MS and MS/MS
spectra, respectively. The MS/MS analyses were performed using
collision energy of 1 kV and collision gas pressure of 1.3 106 Torr.
MS peaks with a signal-to-noise ratio above 15 were listed, and the
15 strongest precursors with a signal-to-noise ratio above 50 among
the MS peaks were automatically selected for MS/MS acquisition (see
Supplementary Data 1–3). A mass filter was used to exclude autolytic
peptides of trypsin.
The resulting data were analyzed using the GPS Explorer 3.6
(Applied Biosystems) software. Proteins were identified by search-
ing against the human subset of the Swissprot protein database
(Swiss Institute of Bioinformatics, Basel, Switzerland) (release 54.6;
4 December 2007) using the MASCOT 2.1.0 search algorithm
(Matrix Science, London, UK). The general parameters for the
peptide mass fingerprinting search were considered to allow maxi-
mum one missed cleavage, ±50 p.p.m. of peptide mass tolerance,
variable methionine oxidation, and fixed cysteine carbamidomethyl-
ation. Probability-based molecular weight search scores were
estimated by comparison of the search results against the estimated
random match population, and were reported as 10log10(p) where
p is the absolute probability. MOWSE scores 455 were considered
significant (Po0.05) for peptide mass fingerprinting. A peptide
charge state of þ 1 and fragment mass tolerance of ±0.25Da were
used for the MS/MS ion search. Individual MS/MS ions scores 428
indicated identity or extensive homology (Po0.05) for the MS/MS
ion search.
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